The Use of Dispensary-Obtained Tetrahydrocannabinol as a Treatment for Neuropsychiatric Symptoms of Dementia

References (26)

1. World Health Organization. Global action plan on the public health response to dementia: 2017–2025. WHO website. https://apps.who.int/iris/bitstream/handle/10665/259615/9789241513487-eng.pdf?sequence=1. 2017. Accessed February 2, 2023.
2. Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015-2060) in adults aged ≥65 years. Alzheimers Dement. 2019;15(1):17–24. PubMed CrossRef
3. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326–1334. PubMed CrossRef
4. Radue R, Walaszek A, Asthana S. Chapter 24 - Neuropsychiatric symptoms in dementia. Handbook of Clinical Neurology. Dekosky ST, Asthana S, eds. Vol 167, Geriatric Neurology. Elsevier, 2019;437–454. https://www.sciencedirect.com/science/article/pii/B9780128047668000248. Accessed September 13, 2021.
5. Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–1483. PubMed CrossRef
6. Okura T, Langa KM. Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Dis Assoc Disord. 2011;25(2):116–121. PubMed CrossRef
7. Phan SV, Osae S, Morgan JC, et al. Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA. Drugs R D. 2019;19(2):93–115. PubMed CrossRef
8. Banerjee S, Murray J, Foley B, et al. Predictors of institutionalisation in people with dementia. J Neurol Neurosurg Psychiatry. 2003;74(9):1315–1316. PubMed CrossRef
9. Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–481. PubMed CrossRef
10. Kales HC, Gitlin LN, Lyketsos CG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769. PubMed CrossRef
11. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. PubMed CrossRef
12. Farlow MR, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol. 2017;27(3):217–231. PubMed CrossRef
13. Meeks TW, Jeste DV. Beyond the black box: what is the role for antipsychotics in dementia? Curr Psychiatr. 2008;7(6):50–65. PubMed
14. Schneider LS, Tariot PN, Dagerman KS, et al; CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–1538. PubMed CrossRef
15. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–546. PubMed CrossRef
16. American Geriatrics Society. Choosing Wisely website. https://www.choosingwisely.org/societies/american-geriatrics-society/. Accessed February 24, 2015, November 5, 2022.
17. Porsteinsson AP, Drye LT, Pollock BG, et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691. PubMed CrossRef
18. Ehrhardt S, Porsteinsson AP, Munro CA, et al; S-CitAD Research Group. Escitalopram for agitation in Alzheimer’s disease (S-CitAD): methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019;15(11):1427–1436. PubMed CrossRef
19. Hillen JB, Soulsby N, Alderman C, et al. Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Ther Adv Drug Saf. 2019;10:2042098619846993. PubMed CrossRef
20. Walther S, Halpern M. Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals (Basel). 2010;3(8):2689–2708. PubMed CrossRef
21. Bahji A, Meyyappan AC, Hawken ER. Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review and meta-analysis. Can J Psychiatry. 2020;65(6):365–376. PubMed CrossRef
22. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. PubMed CrossRef
23. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314. PubMed CrossRef
24. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. PubMed CrossRef
25. Sachs J, McGlade E, Yurgelun-Todd D. Safety and toxicology of cannabinoids. Neurotherapeutics. 2015;12(4):735–746. PubMed CrossRef
26. Palace ZJ, Reingold DA. Medical cannabis in the skilled nursing facility: a novel approach to improving symptom management and quality of life. J Am Med Dir Assoc. 2019;20(1):94–98. PubMed CrossRef